Skin Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Skin Cancer Diagnostics and Therapeutics Market Growth Trends and is Segmented by Cancer Type (Melanoma and Non-melanoma), Type (Diagnosis (Dermatoscopy, Biopsy, Genetic Tests and Others) and Therapeutics (Chemotherapy, Immunotherapy, Targeted Therapy, and Others)), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Forecasts are Provided in terms of Value (in USD million) for the Above Segments.

Skin Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Skin Cancer Diagnostics and Therapeutics Market Size

Skin Cancer Diagnostics and Therapeutics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 14.54 Billion
Market Size (2030) USD 18.74 Billion
CAGR (2025 - 2030) 5.21 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Skin Cancer Diagnostics and Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Skin Cancer Diagnostics and Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Skin Cancer Diagnostics and Therapeutics Market Analysis

The Global Skin Cancer Diagnostics and Therapeutics Market size is estimated at USD 14.54 billion in 2025, and is expected to reach USD 18.74 billion by 2030, at a CAGR of 5.21% during the forecast period (2025-2030).

The outbreak of the COVID-19 pandemic had a significant impact on the market studied. After the pandemic began, the World Health Organization (WHO) guidelines suggested that chronic disease patients remain indoors. Hence, this hampered the skin cancer diagnostic market. However, the surge in the number of research for studying the impact of the treatment delay on patients with non-melanoma skin cancer (NMSC) or melanoma cancer amid Covid-19 increased. A study, 'The impact of the Covid-19 pandemic on quality of life in skin cancer patients' published in August 2021, mentioned that due to an immunocompromised/-suppressed status and dependent on the underlying tumor disease and burden, cancer patients might be at an increased risk of developing severe Covid-19 disease and requiring treatment in an intensive care setting. Thus, the increased skin cancer incidences during the pandemic increased the diagnostics for the same and created demand for new advanced therapeutics for treatment. Therefore, the pandemic is predicted to have a positive impact on skin cancer diagnostics and therapeutics during the pandemic phase.

Certain factors driving the market growth include increasing incidence of skin cancer, extensive research and development (R&D) pipelines, and rising awareness about skin cancer. For instance, updated in February 2022 by the American Society of Clinical Oncology, an estimated 324,635 people were diagnosed with melanoma in 2020, and in 2020, about 2,400 cases of melanoma were estimated to be diagnosed in people aged 15 to 29 in the United States. Thus, the prevalence of skin cancer among the population is augmenting the growth of the market studied.

Moreover, the increased R&D is predicted to drive the demand for skin cancer therapeutics over the forecast period. For instance, in January 2022, Immunocore, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, received approval from the United States Food and Drug Administration (FDA) for KIMMTRAK (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Additionally, In April 2022, barnaclànic+ launched its Dermatological Diagnosis Unit for the diagnosis and treatment of skin cancer, and the new unit will also have the latest technology on the market in dermatological diagnosis and skin cancer. Thus, this increasing R&D is expected to drive the growth of the studied market.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However, the excessive cost associated with therapies and stringent regulatory frameworks is expected to hinder the market growth over the forecast period.

Skin Cancer Diagnostics and Therapeutics Industry Overview

The skin cancer diagnostics and therapeutics market is competitive globally and regionally. The market consists of several major players who are engaged in continuous product development and launches. Some companies currently dominating the market are Abbott, Pfizer Inc., Sanofi SA, F. Hoffmann-La Roche Ltd, Labcorp., and sun pharmaceuticals industries limited, among others.

Skin Cancer Diagnostics and Therapeutics Market Leaders

  1. Amgen, Inc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd

  4. Merck & Co., Inc.

  5. Sun Pharmaceutical Industries Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Skin Cancer Diagnostics and Therapeutics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Skin Cancer Diagnostics and Therapeutics Market News

  • In March 2022, the United States Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab.
  • In January 2022, SkinCure Oncology focused on providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT) and launched GentleCure.com, a consumer health education platform offering evidence-based treatment options for basal cell (BCC) and squamous cell skin cancers (SCC).

Skin Cancer Diagnostics and Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Skin Cancer
    • 4.2.2 Rising Awareness About Skin Cancer
    • 4.2.3 Extensive Research and Developments
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with Therapy
    • 4.3.2 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Cancer Type
    • 5.1.1 Melanoma
    • 5.1.2 Non-melanoma
  • 5.2 By Type
    • 5.2.1 Diagnosis
    • 5.2.1.1 Dermatoscopy
    • 5.2.1.2 Biopsy
    • 5.2.1.3 Genetic Tests
    • 5.2.1.4 Others
    • 5.2.2 Therapeutics
    • 5.2.2.1 Chemotherapy
    • 5.2.2.2 Immunotherapy
    • 5.2.2.3 Targeted Therapy
    • 5.2.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Amgen, Inc.
    • 6.1.3 Pfizer Inc.
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Sanofi
    • 6.1.7 Merck & Co., Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 QIAGEN
    • 6.1.10 Sun Pharmaceutical Industries Ltd
    • 6.1.11 Daiichi Sankyo Company, Limited
    • 6.1.12 Labcorp
    • 6.1.13 Sirnaomics, Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Skin Cancer Diagnostics and Therapeutics Industry Segmentation

As per the scope of the report, skin cancer is the abnormal growth of skin cells and most often develops on skin exposed to the sun. This is a generic form of cancer that can also occur on areas of skin not ordinarily exposed to sunlight.

The skin cancer diagnostics and therapeutics market is segmented by Cancer Type (Melanoma and Non-melanoma), Type (Diagnosis (Dermatoscopy, Biopsy, Genetic Tests, and Others), Therapeutics (Chemotherapy, Immunotherapy, Targeted Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for the above segments.

By Cancer Type Melanoma
Non-melanoma
By Type Diagnosis Dermatoscopy
Biopsy
Genetic Tests
Others
Therapeutics Chemotherapy
Immunotherapy
Targeted Therapy
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Skin Cancer Diagnostics and Therapeutics Market Research FAQs

How big is the Global Skin Cancer Diagnostics and Therapeutics Market?

The Global Skin Cancer Diagnostics and Therapeutics Market size is expected to reach USD 14.54 billion in 2025 and grow at a CAGR of 5.21% to reach USD 18.74 billion by 2030.

What is the current Global Skin Cancer Diagnostics and Therapeutics Market size?

In 2025, the Global Skin Cancer Diagnostics and Therapeutics Market size is expected to reach USD 14.54 billion.

Who are the key players in Global Skin Cancer Diagnostics and Therapeutics Market?

Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc. and Sun Pharmaceutical Industries Ltd are the major companies operating in the Global Skin Cancer Diagnostics and Therapeutics Market.

Which is the fastest growing region in Global Skin Cancer Diagnostics and Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Skin Cancer Diagnostics and Therapeutics Market?

In 2025, the North America accounts for the largest market share in Global Skin Cancer Diagnostics and Therapeutics Market.

What years does this Global Skin Cancer Diagnostics and Therapeutics Market cover, and what was the market size in 2024?

In 2024, the Global Skin Cancer Diagnostics and Therapeutics Market size was estimated at USD 13.78 billion. The report covers the Global Skin Cancer Diagnostics and Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Skin Cancer Diagnostics and Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Skin Cancer Diagnostics and Therapeutics Industry Report

Statistics for the 2025 Global Skin Cancer Diagnostics and Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Skin Cancer Diagnostics and Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.